Literature DB >> 9763504

Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.

Y Siegman-Igra1, R Ravona, H Primerman, M Giladi.   

Abstract

OBJECTIVES: To review current experience with Pseudomonas aeruginosa bacteremia and compare outcome of patients treated with single-drug, versus combination therapy.
METHODS: The charts of all patients with P. aeruginosa bacteremia between 1990 and 1992 were reviewed, and pertinent demographic, clinical, and bacteriologic data were retrieved. In addition, similar data were collected from a series of patients with P. aeruginosa bacteremia from the literature of the past 20 years.
RESULTS: One hundred and twenty-three episodes of P. aeruginosa bacteremia in 121 patients were identified. Most patients were older than 70 years, had at least one underlying condition, and had acquired the infection in the hospital. Attributable mortality was 34%. After exclusion for early mortality and inappropriate therapy, 57 patients remained eligible for comparison of outcome according to therapy protocol. Mortality from infection was equal between the group of 42 patients who received monotherapy and the 15 patients who received combination therapy (14% and 13%, respectively). The literature review revealed eight articles describing 21 to 410 episodes of Pseudomonas bacteremia. The clinical characteristics of these series did not differ significantly from those of the present series.
CONCLUSIONS: Incidence, epidemiology, clinical characteristics, and outcome of pseudomonas sepsis did not change significantly over the past 2 decades. Appropriate monotherapy was as effective as combination drug therapy for individuals with pseudomonas bacteremia surviving the first 2 days of infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763504     DOI: 10.1016/s1201-9712(98)90055-8

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  19 in total

1.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

3.  Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.

Authors:  L A Ruiz; A Gómez; C Jaca; L Martínez; B Gómez; R Zalacain
Journal:  Infection       Date:  2010-09-29       Impact factor: 3.553

4.  [Impairment of oxygenation of patients in surgical intensive care : Early symptom of severe sepsis].

Authors:  M Hückstädt; G O Hofmann; T Mendel; R Stuttmann; P Hilbert-Carius
Journal:  Anaesthesist       Date:  2016-10-05       Impact factor: 1.041

Review 5.  Optimizing antibiotic therapy in the intensive care unit setting.

Authors:  M H Kollef
Journal:  Crit Care       Date:  2001-06-28       Impact factor: 9.097

6.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

7.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

8.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

9.  [Antimicrobial combination therapy].

Authors:  Günter Weiss
Journal:  Wien Med Wochenschr       Date:  2003

Review 10.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Authors:  Mical Paul; Ishay Benuri-Silbiger; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2004-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.